Edgewise Therapeutics (NASDAQ:EWTX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Edgewise Therapeutics (NASDAQ:EWTX) from a hold rating to a sell rating in a report issued on Saturday morning.

EWTX has been the subject of a number of other research reports. Stifel Nicolaus set a $25.00 price objective on shares of Edgewise Therapeutics in a report on Thursday. Wedbush decreased their price target on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, November 7th. JPMorgan Chase & Co. upped their price objective on Edgewise Therapeutics from $33.00 to $34.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Royal Bank Of Canada increased their price objective on Edgewise Therapeutics from $49.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Edgewise Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $36.36.

Edgewise Therapeutics Trading Up 2.6%

Shares of NASDAQ EWTX opened at $30.44 on Friday. The stock has a market capitalization of $3.22 billion, a PE ratio of -18.67 and a beta of 0.27. Edgewise Therapeutics has a twelve month low of $10.60 and a twelve month high of $31.82. The stock has a fifty day simple moving average of $27.62 and a 200-day simple moving average of $21.22.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its earnings results on Thursday, February 26th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, equities analysts predict that Edgewise Therapeutics will post -1.45 earnings per share for the current year.

Insider Transactions at Edgewise Therapeutics

In other news, Director Badreddin Edris sold 115,471 shares of the stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $29.44, for a total value of $3,399,466.24. Following the transaction, the director owned 19,820 shares in the company, valued at approximately $583,500.80. This represents a 85.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 23.20% of the stock is owned by company insiders.

Institutional Trading of Edgewise Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bessemer Group Inc. boosted its holdings in shares of Edgewise Therapeutics by 1,170.3% in the 3rd quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock valued at $38,000 after buying an additional 2,165 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in Edgewise Therapeutics in the second quarter valued at $45,000. Jones Financial Companies Lllp purchased a new position in shares of Edgewise Therapeutics during the first quarter worth about $47,000. Seven Fleet Capital Management LP acquired a new stake in shares of Edgewise Therapeutics during the fourth quarter worth about $50,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Edgewise Therapeutics by 23.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $71,000 after purchasing an additional 550 shares during the last quarter.

Key Headlines Impacting Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.